GET DAILY SIGNALSPfizer (PFE) Posts Steady Q3 Results as Portfolio Shifts Gain Traction
Key Takeaways
- Pfizer reported third-quarter 2026 revenue of $16.58 billion, roughly flat year over year but ahead of analyst consensus estimates.
- Reported diluted EPS came in at $0.56, while adjusted diluted EPS was $0.87, topping Wall Street expectations.
- Non-COVID products grew 7% operationally, and launched and acquired products surged 32%, offsetting steep declines in Comirnaty and Paxlovid.
- Management raised full-year 2026 revenue guidance to $62.0–$64.0 billion and narrowed adjusted EPS guidance to $2.95–$3.05.
- Pfizer appointed Cecile Guegan as Chief Financial Officer, effective November 1, 2026.
Why These Results Matter in the Broader Transition
Pfizer continues working through a well-documented shift away from pandemic-era products. With Comirnaty and Paxlovid sales normalizing lower, attention centers on whether newer and acquired medicines can sustain growth. The third-quarter update offered a useful checkpoint on commercial execution and the ongoing cost-realignment effort. Momentum in areas such as Eliquis, Padcev, the Vyndaqel family, Nurtec, and Lorbrena now sits at the heart of the investment thesis, while the obesity and oncology pipeline offers longer-term potential. The decision to raise guidance reflected management’s confidence even as loss-of-exclusivity pressures remain.
Quarterly Performance Breakdown
For the third quarter of 2026, PFE reported revenue of $16.58 billion, essentially flat on both a reported and operational basis versus $16.65 billion a year earlier. The figure exceeded consensus estimates of roughly $16.1 billion. Reported diluted EPS was $0.56, down from $0.62 a year ago, while adjusted diluted EPS held at $0.87, above the analyst consensus range of about $0.72 to $0.73.
Growth came from the non-COVID portfolio, which rose 7% operationally, and from launched and acquired products, which advanced 32% operationally. Eliquis increased 25%, Padcev rose 55%, the Vyndaqel family climbed 12%, Nurtec ODT/Vydura advanced 33%, and Lorbrena gained 43% operationally. These gains were offset by Paxlovid, down 63%, Comirnaty, down 29%, and the Prevnar family, down 10%. Adjusted R&D spending rose 18% operationally as the company invested in oncology and obesity programs. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Pfizer raised full-year 2026 revenue guidance by $1.5 billion at the midpoint to $62.0–$64.0 billion and narrowed adjusted diluted EPS guidance to $2.95–$3.05, up from $2.80–$3.00 previously.
Market Reaction and What Investors Are Focusing On
The response to the report was measured despite the headline beats. PFE shares moved only modestly around the release, with some sessions showing a slight decline of roughly 1% even as pre-market indications initially ticked higher. The restrained reaction reflects investor emphasis on the still-flat overall revenue picture and the ongoing drag from COVID-19 products and the Prevnar franchise, rather than the adjusted EPS outperformance. The raised guidance and 32% growth in launched and acquired products were viewed positively, yet markets continue to weigh near-term LOE headwinds and the pace of the portfolio transition.
Key Areas to Watch Going Forward
Looking ahead, several factors will shape PFE’s path. The commercialization of the obesity portfolio stands out as a key variable. Management plans to advance roughly 10 active and planned Phase 3 trials in 2026, including work on the investigational monthly GLP-1 peptide berobenatide, with potential first approvals targeted for 2028.
Oncology execution will also matter. The legacy Seagen portfolio grew 39% year over year in the U.S., and further uptake of Padcev, along with late-stage readouts such as Elrexfio in multiple myeloma and the next-generation CDK4 inhibitor atirmociclib, could strengthen the growth story.
Cost discipline remains on track to deliver nearly all of the targeted $7.2 billion in net savings by the end of 2026, with an additional $2.5 billion expected from 2027 through 2029. Investors will also monitor COVID-19 product guidance of approximately $4 billion for the full year and how the newly appointed CFO approaches capital allocation, dividends, and potential share repurchases.
Refining Research with AI Tools
In my own workflow, I frequently use Tickeron’s AI Screener to quickly filter opportunities across sectors and compare names like PFE against peers on both technical and fundamental metrics. It helps surface patterns and signals that complement traditional analysis without replacing it. This kind of tool has become a regular part of how I prepare for earnings seasons and portfolio reviews.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PFE's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for PFE turned positive on October 14, 2026. Looking at past instances where PFE's MACD turned positive, the stock continued to rise in 23 of 42 cases over the following month. The odds of a continued upward trend are 55%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on PFE as a result. In 43 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 49%.
Following a +2.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where PFE advanced for three days, in 152 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
The Aroon Indicator entered an Uptrend today. In 87 of 196 cases where PFE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 44%.
Bearish Trend Analysis
The 10-day RSI Indicator for PFE moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 15 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 56%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PFE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 20 (best 1 - 100 worst), indicating outstanding price growth. PFE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.052) is normal, around the industry mean (-1.476). P/E Ratio (39.831) is within average values for comparable stocks, (21.871). Projected Growth (PEG Ratio) (13.137) is also within normal values, averaging (5.738). Dividend Yield (0.056) settles around the average of (0.038) among similar stocks. P/S Ratio (2.469) is also within normal values, averaging (4.033).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PFE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of vaccines and injectable biologic medicines
Industry PharmaceuticalsMajor
Advertisement